Physician profile
John E Mclachlan
NPI 1457331761
$9,260.02
in general payments reported to CMS, 2019-2025
39 companies · $830 in 2025
The $830 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,363 · 2020: $842 · 2021: $665 · 2022: $1,860 · 2023: $2,372 · 2024: $1,330 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,531.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,087.49 | 2019-2024 | Xarelto |
| Medtronic, INC. | $1,000.22 | 2021-2024 | Corevalve Evolut R, Resolute Onyx, Linq II |
| E.R. Squibb & Sons, L.L.C. | $804.10 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $797.89 | 2019-2025 | Repatha, Otezla, Repatha |
| Abiomed | $643.10 | 2020-2025 | Impella |
| Shockwave Medical, INC | $531.99 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Esperion Therapeutics, INC. | $511.62 | 2020-2024 | Nexletol, Nexlizet |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $504.66 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $502.18 | 2019-2025 | |
| Medtronic Vascular, INC. | $496.20 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.41 | 2019-2024 | Jardiance |
| Pfizer INC. | $276.26 | 2019-2024 | |
| Boston Scientific Corporation | $266.88 | 2019-2025 | Watchman Flx, Watchman |
| Astrazeneca Pharmaceuticals Lp | $223.23 | 2020-2024 | Farxiga |
| Ancora Heart, INC. | $155.04 | 2025 | Accucinch |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mclachlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.